Key result
Pulmonary artery banding linked to improved 5-year LVEF vs medical therapy alone in pediatric cardiomyopathy.
Why the study?
The suitability of pulmonary artery banding as a treatment strategy for dilated cardiomyopathy and left ventricular non-compaction cardiomyopathy with depressed left ventricular ejection fraction needed to be assessed.
Does pulmonary artery banding combined with medical therapy improve left ventricular ejection fraction in patients with dilated or non-compaction cardiomyopathy with LVEF <35%?
Cohort (n=21)
No
Does pulmonary artery banding combined with medical therapy improve left ventricular ejection fraction in patients with dilated or non-compaction cardiomyopathy with LVEF <35%?
Pulmonary artery banding combined with anti-congestion medication significantly improves left ventricular ejection fraction and cardiac restoration indices in patients with dilated and non-compaction cardiomyopathy compared to medical therapy alone.
Answers are grounded in this paper and cite their sources.
Pulmonary artery banding may improve LVEF in select pediatric DCM/LVNC cases; leaves open its role pending larger prospective studies.
Objectives: To retrospectively assess the suitability of pulmonary artery banding as a treatment strategy for dilated cardiomyopathy and left ventricular non-compaction cardiomyopathy with depressed left ventricular ejection fraction. Methods: The study was retrospective and included consecutive patients who met the inclusion criteria: diagnosed with dilated cardiomyopathy or left ventricular non-compaction cardiomyopathy and left ventricular ejection fraction less than 35%. Cardiac indices were documented, and clinical outcomes were followed for 5 years. Results: This study included 21 patients with depressed left ventricular ejection fraction due to dilated cardiomyopathy (n = 11) or left ventricular non-compaction cardiomyopathy (n = 10), treated either with anti-congestion medication alone or in combination with pulmonary artery banding. The groups treated with pulmonary artery banding showed significant improvement in left ventricular ejection fraction compared to controls (ANOVA, p = 0.0002), with no major adverse events. In the subgroup with left ventricular non-compaction, pulmonary artery banding led to significant improvement of the left ventricular ejection fraction (p = 0.00002) and significant reductions in the Z scores of left ventricular end-diastolic diameter (p = 0.0002) and of end-diastolic volume (p = 0.004). Conclusions: Pulmonary artery banding appears to be a viable strategy for improving heart function in patients with non-compaction and dilated cardiomyopathy and depressed left ventricular ejection fraction. While pulmonary artery banding demonstrated more pronounced benefits in the subgroup with non-compaction cardiomyopathy, significantly enhancing cardiac restoration indices throughout the follow-up period, warranting further investigation in larger studies.
No takes yet. Share an insight, caveat, or question.
Semyashkin et al. (2025) conducted a cohort in Dilated cardiomyopathy or left ventricular non-compaction cardiomyopathy with depressed LVEF (n=21). Pulmonary artery banding vs. Anti-congestion medication alone was evaluated on Left ventricular ejection fraction (LVEF) (p=0.0002). Pulmonary artery banding improved left ventricular ejection fraction over 5 years compared to anti-congestion medication alone in pediatric patients with dilated or non-compaction cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: